| 1. |
- Bertenstam, J, et al.
(författare)
-
THE WAXHOLM APPLICATION DATABASE
- 1995
-
Konferensbidrag (refereegranskat)abstract
- This paper describes an application database collected in Wizard-of-Oz experiments in a spoken dialogue system, WAXHOLM. The system provides information on boat traffic in the Stockholm archipelago. The database consists of utterance-length speech files, their corressonding transcriptions, and log files of the dialogue sessions. In addition to the spontaneous dialogue speech, the material also comprise recordings of phonetically balanced reference sentences uttered by all 66 subjects. In the paper the recording procedure is described as well as some characteristics of the speech data and the dialogue.
|
|
| 2. |
- Högberg, Lotta, et al.
(författare)
-
Intranasal versus intravenous administration of midazolam to children undergoing small bowel biopsy
- 1995
-
Ingår i: Acta Paediatrica. - : Wiley. - 0803-5253 .- 1651-2227. ; 84:12, s. 1429-1431
-
Tidskriftsartikel (refereegranskat)abstract
- Sixty-three children under the age of 9 years were randomized to receive intravenous (group A, n= 33) or intranasal (group B, n= 30) midazolam as sedation for small bowel biopsy. Mean doses of midazolam given to produce adequate sedation were 0.31 mg (kg body weight)−1 in group A and 0.34 mg (kg body weight)−1 in group B (NS). Four children in group A and 10 children in group B required additional doses to maintain adequate sedation throughout the biopsy procedure (p <0.05). There was no significant difference between the groups regarding the median procedure time (7 min in group A, 8.5 min in group B) or median fluoroscopy time (5 s in group A, 4 s in group B). All children in group B showed signs of discomfort from the nose when given midazolam intranasally. In conclusion, this study indicates that intravenous administration of midazolam is preferable to the intranasal route.
|
|
| 3. |
- Mogren, I, et al.
(författare)
-
Characteristics of pregnancy and birth and malignancy in the offspring (Sweden).
- 1999
-
Ingår i: Cancer Causes and Control. - 0957-5243 .- 1573-7225. ; 10:1, s. 85-94
-
Tidskriftsartikel (refereegranskat)abstract
- Although some associations, the consistent pattern of non-association indicated a low impact of intrauterine environment or changed genetic material on the future development of malignancy in the offspring up to early middle-age.
|
|
| 4. |
- Norin, L, et al.
(författare)
-
Deposition of transition metal carbide superlattices using C-60 as a carbon source
- 1998
-
Ingår i: Applied Physics Letters. ; 73:19, s. 2754-2756
-
Tidskriftsartikel (refereegranskat)abstract
- Epitaxial films of TiC and VC can be deposited at low temperatures on Mg(001) substrates by coevaporation of the metals with C-60 in a ultrahigh vacuum system. This process was used to deposit TiC/VC (001) superlattices on MgO(001) at 400 degrees C. The
|
|
| 5. |
- Sorbe, B G, et al.
(författare)
-
Navoban (tropisetron) alone and in combination with dexamethasone in the prevention of chemotherapy-induced nausea and vomiting : the Nordic experience. The Nordic Antiemetic Trial Group
- 1995
-
Ingår i: Anti-Cancer Drugs. - : Ovid Technologies (Wolters Kluwer Health). - 0959-4973 .- 1473-5741. ; 6:Suppl 1, s. 6-31
-
Tidskriftsartikel (refereegranskat)abstract
- To evaluate the efficacy and safety of Navoban (tropisetron) three different Nordic multicentre trials were conducted during the period 1988-92. In all, 1050 patients were recruited from 15 centres. In the first study, Navoban monotherapy was compared with a high-dose metoclopramide cocktail. In the second, Navoban +/- dexamethasone was evaluated for those patients not fully protected by Navoban alone. In the third trial, Navoban was evaluated for various chemotherapy regimens, for long-term efficacy, and for various risk groups of patients. Spontaneous intercycle variations were also evaluated. Navoban was found to be as effective as the antiemetic cocktail but with a more favourable spectrum of side effects and a simpler schedule of administration. Navoban was more effective during the acute than the delayed phase. Addition of dexamethasone significantly improved prevention of both acute and delayed emesis. Long term efficacy seemed to be stable up to 10 cycles of chemotherapy. Patients treated with noncisplatin regimens showed significantly higher protection rates than patients treated with cisplatin. Various cancer diagnoses and cytostatic agents were also evaluated. Gender and age were important risk factors. Navoban was found to be an efficacious antiemetic agent, especially regarding acute nausea and vomiting. Addition of a corticosteroid significantly improved the effect during highly emetogenic chemotherapy. The role of Navoban for delayed emesis must be evaluated in future trials. The two most common side effects were headache and constipation. Overall, Navoban was well tolerated and patient compliance with the drug was high.
|
|
